MiMedx Group, Inc. reported strong fourth quarter and full year 2024 results, with net sales growing 7% year-over-year for the quarter to $93 million and Adjusted EBITDA margin at 21% of net sales. The company also generated strong free cash flow, despite challenges in Medicare reimbursement.
Net sales for Q4 2024 increased by 7% year-over-year to $93 million.
Adjusted EBITDA for Q4 2024 was $20 million, representing 21% of net sales.
Gross profit for Q4 2024 was $76 million, an increase of $3 million compared to the prior year period.
The company maintained a strong cash position, with $104 million in cash and cash equivalents as of December 31, 2024.
Provided that future effective LCDs go into effect as currently planned, MIMEDX expects net sales growth of at least high single-digits as a percentage and Adjusted EBITDA margin above 20% for the full-year 2025. Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an Adjusted EBITDA margin above 20%.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance